News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

How AbbVie (ABBV), Gilead (GILD), Pfizer (PFE) Are All Gaining From Eli Lilly (LLY)'s RA Rejection Pain



4/18/2017 6:07:02 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Three pharma stocks that stand to benefit from the announcement by Eli Lilly & Co. and Incyte that the FDA rejected their rheumatoid arthritis pill baricitinib were up Monday.

Gilead Sciences shares rose 56 cents in early trading Monday to $67.06 while Pfizer was up 9 cents to $33.97 and Abbvie up 38 cents to $64.51.

In a statement Friday, Lilly said the FDA has requested additional clinical data to determine appropriate doses of baricitinib. The FDA also asked for more safety data.

Read at The Street.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES